Compare Natera Inc. Common Stock (NTRA) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while iShares 1 3 Year Treasury Bond ETF trades at $81.3 (market cap $26.87B). The key difference: Natera Inc. Common Stock is far larger — about 2.1× iShares 1 3 Year Treasury Bond ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and iShares 1 3 Year Treasury Bond ETF for 64 Days on average.
| NTRA | SHY | |
|---|---|---|
Market Cap | $57.03B | $26.87B |
Volume | 1,131,157 | 3,180,822 |
Sector | Health | Fixed Income |
52-Week High | $425.64 | $83.18 |
52-Week Low | $179.42 | $81.05 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
SHY, a US stock, trades at $81.19 with minimal daily movement, reflecting stability amid broader bond market volatility. Technical indicators show a bearish trend with moving averages signaling caution, while oscillators remain neutral. Recent dividend actions provide income, but key financial ratios are unavailable. The stock's price action is tightly range-bound with support and resistance near $81.
The outlook for SHY is cautious due to bearish technical signals and a lack of fundamental data. Risks include interest rate sensitivity and macroeconomic pressures from rising bond yields. Investment opportunities may lie in its dividend yield if fundamentals strengthen, but current sentiment and technicals suggest limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
